Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Neoadjuvant Spartalizumab and Canakinumab for the Treatment of Patients with Localized Kidney Cancer, SPARC-1 Trial

Trial Status: closed to accrual

This pilot phase Ib trial studies the side effects and how well spartalizumab and canakinumab work in treating patients with kidney cancer that that has not spread to other parts of the body (localized). Immunotherapy with monoclonal antibodies, such as spartalizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Immunotherapy with canakinumab may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Giving spartalizumab and canakinumab before surgery may work better than giving no treatment before surgery in treating kidney cancer.